Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 37, showing 5 Applications out of 183 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s)

1.

ECCT/24/10/02   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county)
 
View

2.

ECCT/24/09/02   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE   
Principal Investigator(s)
1. Teresa Kinyari
Site(s) in Kenya
1. University of Nairobi Clinical Research Centre (Nairobi City county)
2. KEMRI-Mtwapa Clinical Annex (Kilifi county)
3. Center for Research In Tropical Medicine and Community Development (Nairobi City county)
4. Clinical Research Health Network (CREA-N) (Machakos county)
5. KEMRI-CRDR Clinical Research Annex (Nairobi City county)
 
View

3.

ECCT/24/07/05   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Bernhards Ogutu
Site(s) in Kenya
1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county)
 
View

4.

ECCT/24/06/07   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Charity Wambui Kanyoro
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

5.

ECCT/24/06/04   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
 
View